Introduction
============

Since its introduction as an alternative to continuous positive airway pressure (CPAP) in preterm infants, high-flow nasal cannula (HFNC) oxygenation has been widely used for various respiratory conditions in adults and neonates \[[@b1-kjp-2019-00626],[@b2-kjp-2019-00626]\]. Because of its easy application, effectiveness, and relatively good safety, HFNC is considered an essential intensive care device. Indications for HFNC in preterm infants include initial noninvasive respiratory support (NRS) after birth and the prevention of reintubation. Despite broader indications in adults, the efficacy of HFNC in children has been demonstrated limitedly after the first use in acute bronchiolitis. This review focuses on indications, flow settings, responder evaluation, and safety of HFNC in children.

Current understanding of action mechanism
=========================================

The full name of HFNC is heated humidified HFNC oxygen therapy. Adjustable (FiO~2~ 21%--100%) heated (34°C--37°C) oxygen with nearly 100% relative humidity can avoid mucosal injury and patient discomfort from cold, dry air. Heated humidification can encourage the clearance of secretions and reduce bronchoconstriction. The basic principle of HFNC is to set a higher oxygen flow than inspiratory demand flow according to the clinical situation. This can lead washout of the upper airways, decreased nasal resistance, and reduced dead space \[[@b3-kjp-2019-00626]\]. Current studies revealed that HFNC induces positive airway pressure to lead alveolar recruitment of collapsed lesions and the elevation of functional residual capacity \[[@b4-kjp-2019-00626],[@b5-kjp-2019-00626]\]. Additionally, HFNC reduces the inflow of ambient air, minimizes the dilution of wanted gas composition, and improves oxygenation \[[@b6-kjp-2019-00626]\]. There is no age-dependent differentiation between adults and children in its mechanism of action.

Flow setting and cannula size for pediatric patients
====================================================

The aforementioned principle, a higher flow setting than inspiratory demand, can be applied to patients of all ages. Airway pressure generated from a high-flow system varies and depends on flow amount, cannula and nares sizes, and degree of mouth opening in an experimental study \[[@b7-kjp-2019-00626]\]. In the experimental setting, positive lung-distending pressure increased as the flow increased from 0 to 12 L/min \[[@b8-kjp-2019-00626]\]. Recent studies reported that limited pressure delivery of 2--4 cmH2O was measured in the pharynx and esophagus in children and adults with HFNC \[[@b9-kjp-2019-00626]-[@b11-kjp-2019-00626]\].

There is a lack of guidance about optimal flow in pediatric patients. Important randomized controlled studies conducted in patients with acute bronchiolitis provided information about appropriate flow \[[@b12-kjp-2019-00626]-[@b14-kjp-2019-00626]\]. Patients younger than 24 months of age tolerated the flow of 1--2 L/kg/min (up to 20 L/min) and 3 L/kg/min. However, patients were uncomfortable with 3 L/kg/min despite the same efficacy \[[@b14-kjp-2019-00626]\]. Considering the flow limitation in adults (50--60 L/min), the reasonable flow rate is thought to be 1--2 L/kg/min up to 10 kg in patients, followed by an increase of 0.5 L/kg/min. One study comparing the efficacy of HFNC and CPAP noted no differences in length of stay in the intensive care unit (ICU) and the need for mechanical ventilation between 2 L/kg/min of HFNC and 7 cmH2O of CPAP \[[@b15-kjp-2019-00626]\]. Interestingly, there was a large variation of maximal flow rates (L/min) in the different age groups among 67 hospitals \[[@b16-kjp-2019-00626]\]. These results showed the importance of comprehensive understanding of the mechanism and optimal flow to ensure better outcomes.

Cannula size varies by age and body weight. Manufacturers recommend that the cross-sectional area of the cannula be no more than 50% that of the nares because of the risk of unexpected elevations in airway pressure and the following risk of air leak. That means that the appropriate outer diameter of the cannula is no more than two-thirds that of the nares. Recommended flow settings and cannula sizes for pediatric patients are summarized in [Table 1](#t1-kjp-2019-00626){ref-type="table"}.

Indications for HFNC in children
================================

During recent decades, HFNC has been widely used in adult patients. Indications from the evidence in adults include acute hypoxemic respiratory failure, postextubation support, preoxygenation before intubation or during bronchoscopy, postoperative respiratory failure, and acute pulmonary edema \[[@b17-kjp-2019-00626]\]. Many pediatric studies have included patients with acute bronchiolitis. However, other indications have been studied, including asthma, sleep apnea, pneumonia, transport of a critical patient, and postextubation respiratory support \[[@b17-kjp-2019-00626],[@b18-kjp-2019-00626]\].

We should know that contraindications for HFNC include upper airway abnormalities that may make HFNC ineffective or potentially dangerous, life-threatening hypoxia, hemodynamic instability, facial bone or skull base trauma, and pneumothorax. In addition, HFNC should be applied carefully in patients with a decreased level of consciousness, congenital heart disease, acute asthma, or chronic respiratory failure. The recent pediatric studies are summarized in [Table 2](#t2-kjp-2019-00626){ref-type="table"}.

Acute bronchiolitis
===================

Acute bronchiolitis has been the main indication for HFNC in patients older than neonates. Recent studies confirmed the effectiveness of HFNC as rescue therapy in the treatment of moderate to severe bronchiolitis. The first randomized controlled trial (RCT) included 202 patients younger than 24 months with moderate bronchiolitis \[[@b12-kjp-2019-00626]\]. HFNC of 1 L/min/kg with a fraction of inspired oxygen (FiO~2~) of 0.6 was compared with standard low flow (2 L/min). There were no differences in time on oxygen treatment and transfer rate to the ICU, but a lower treatment failure rate was found in the HFNC group. Another large-scale RCT of 1,472 infants \<12 months of age with bronchiolitis confirmed the significantly lower treatment failure rate in the HFNC group than in the standard oxygen group \[[@b13-kjp-2019-00626]\]. There were no differences in duration of hospital stay, duration of oxygen therapy, or ICU admission. These 2 remarkable RCTs concluded that HFNC plays a role in rescue therapy for patients with moderate to severe bronchiolitis and stated that physicians should remember that the first use of HFNC does not modify the disease process. In a recent systematic review of 9 RCTs \[[@b19-kjp-2019-00626]\], there were no differences in length of stay, duration of oxygen therapy, ICU transfer, intubation rate, respiratory rate (RR), SpO~2~, or adverse events in the HFNC versus standard oxygen therapy and nasal CPAP groups. The incidence of treatment failure in the HFNC group was lower than that of the standard oxygen group but higher than that of the nasal CPAP group.

Asthma
======

Limited data support the use of HFNC in children with conditions other than bronchiolitis. However, more clinical evidence is expected soon because HFNC is easily applied with a broad indication in adults and a definite advantage in children with bronchiolitis.

A retrospective observational study conducted in patients with status asthmaticus (N=73) reported improvements in pH, pCO~2~, heart rate (HR), RR, and oxygenation in the HFNC group compared to the standard oxygen group \[[@b20-kjp-2019-00626]\]. Two treatment failures occurred in the HFNC group (n=39): one pneumothorax and one case of other noninvasive support. Another randomized pilot trial of Emergency Department (ED) patients with moderate to severe asthma exacerbation reported an improved pulmonary score in the HFNC group versus the standard oxygen group at 2 hours after treatment \[[@b21-kjp-2019-00626]\]. When using HFNC to treat asthma, physicians must consider optimal inhalation therapies such as a bronchodilator, anticholinergic agents, and inhaled corticosteroids. Because HFNC can reduce the entrainment of ambient air, it inhibits optimal inhalation therapy via a nebulizer. Current evidence reported that the amount of aerosol delivery was meager in an *in vitro* high-flow system \[[@b22-kjp-2019-00626]\]. In this situation, temporary discontinuation of HFNC or lowering the flow to \<5 L/min should be considered at the time of nebulization.

Other indications
=================

Clinical indications reported from 67 pediatric ICU (PICU) and neonatal ICU in Germany included bronchiolitis, respiratory support for preterm infants, pneumonia, severe obstructive bronchitis or asthma, bridging to intubation, and postextubation support \[[@b16-kjp-2019-00626]\]. Apnea, postoperative respiratory support, and upper airway obstruction were also reported, but evidence-based studies are lacking. In the ED, HFNC could be considered for patients with respiratory distress not requiring immediate endotracheal intubation \[[@b23-kjp-2019-00626]\].

In adult studies of acute respiratory failure, HFNC reduced the rates of intubation, mechanical ventilation, and escalation of respiratory support compared to conventional oxygen therapy but showed no better outcomes than noninvasive ventilation \[[@b24-kjp-2019-00626]\]. Acute respiratory failure due to various etiology in children might be treated with HFNC before other respiratory supports according to patient severity and clinical settings. HFNC improved oxygenation by reducing HR in CPAP-intolerant children (N=10) with obstructive sleep apnea syndrome (OSAS) \[[@b25-kjp-2019-00626]\]. Moreover, another study reported improvements in the apneahypopnea index and nadir oxygen saturation in 5 patients with HFNC \[[@b26-kjp-2019-00626]\]. These studies suggested that HFNC could warrant further studies and consideration as alternative OSAS therapies. HFNC therapy improved the respiration rate of pediatric patients with postextubation acute respiratory failure after cardiac surgery \[[@b27-kjp-2019-00626]\]. HFNC showed a lower failure rate after extubation compared with that of the conventional oxygen therapy group in the ICU \[[@b28-kjp-2019-00626]\].

Studies comparing the efficacy and safety of NRSs are rare. One RCT comparing low-flow oxygen, HFNC, and bubble CPAP for children with severe pneumonia and hypoxemia reported no difference in the treatment failure rate after more than 1 hour of treatment between children supported by HFNC and those with bubble CPAP \[[@b29-kjp-2019-00626]\]. This study was stopped early because of the higher mortality rate in the low-flow oxygen group. Although there was no statistical significance in mortality between the HFNC (10 of 79, 13%) and bubble CPAP (3 of 79, 4%) groups, careful interpretation is needed due to flow limitations of HFNC (2 L/kg/min up to the maximum of 12 L/min) in subjects younger than 5 years. Another study comparing HFNC and helmet CPAP in children with respiratory distress aged 1--24 months reported that both improved respiratory distress, although the clinical response to helmet CPAP was more efficient and rapid than that to HFNC \[[@b30-kjp-2019-00626]\]. In 2017, a randomized feasibility trial of NRS including HFNC and CPAP was conducted in critically ill children with primary respiratory failure (group A: step-up NRS) and postextubation support (group B: step-down NRS). This pilot study showed that it was feasible to conduct a large RCT in the pediatric critical care setting \[[@b31-kjp-2019-00626]\].

Identification of efficacy
==========================

Good responders to HFNC generally show improvements in RR, HR, and work of breathing (WOB) within the first 60--90 minutes \[[@b17-kjp-2019-00626]\]. Reductions in apnea and oxygen requirements are also indicative. If the patients showed an increasing oxygen requirement and unchanged or increasing RR, HR, and WOB in this period, adjustment of flow rate and FiO2, another respiratory support and ICU transfer from the ward should be considered. Nonresponders in severe viral bronchiolitis were more likely to have a higher pediatric risk of mortality III scores (PRISM III) \[[@b32-kjp-2019-00626]\]. Therefore, careful observation with a pulse oximeter using a central monitoring system is important for the early detection of aggravation.

Safety issue in children
========================

HFNC is generally safe in the general pediatric ward, ED, and PICU. A well-known complication of HFNC is barotrauma such as air-trapping, pneumothorax, and pneumomediastinum. Serious pneumothorax in children has been infrequently reported \[[@b33-kjp-2019-00626]\]. Careful observation seems mandatory since this was reported even in a low-flow condition (6 L/min in 22-month-old child). The use of an inappropriately large cannula is associated with barotrauma. Abdominal distention and nasal mucosal injury can also occur. Nonadherence to HFNC is sometimes reported in children \[[@b22-kjp-2019-00626]\].

Conclusion
==========

A comparison of clinical outcomes between the pre- and post-HFNC eras was conducted in a PICU \[[@b34-kjp-2019-00626]\]. Significant decreases in intubation rate and total mechanical ventilator days per admission were reported despite no associated changes in mortality. Strong evidence exists for rescue therapy for acute bronchiolitis, while advantages of other indications have been reported. Better designed and controlled studies are needed for other indications and comparisons with other respiratory supports. Although HFNC is a relatively safe, well-tolerated, and feasible method in a general pediatric ward, ED, or ICU, careful monitoring is required to detect nonresponders and potential complications.
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###### 

Recommended flow settings and cannula sizes for high-flow nasal cannula therapy in pediatric patients

  Age               Body weight (kg)   Flow range (L/min)^[a)](#tfn1-kjp-2019-00626){ref-type="table-fn"}^   Manufacturer-recommended cannula size   
  ----------------- ------------------ --------------------------------------------------------------------- --------------------------------------- ------------------------------------------
  ≤1 Month          \<4                5--8                                                                  S, M                                    Neonatal, infant
  1 Month--1 year   4--10              8--20                                                                 M, L                                    Pediatric small
  1--6 Years        10--20             12--25                                                                L, XL                                   Pediatric small, pediatric (adult small)
  6--12 Years       20--40             20--30                                                                XL, small                               Pediatric (adult small),
  12--18 Years      \>40 kg            25--50                                                                Small, medium                           Pediatric (adult small), adult

OD, outer diameter.

Allowed flow range might differ from the manufacturer's recommendations.

XS, S, M, L, and XL Optiflow Junior 2; Small and Medium Optiflow Plus.

###### 

Clinical indications for high-flow nasal cannula therapy in pediatric patients

  Disease, conditions                                                                                                                           Study                                                                      Study design                                                                 Subjects characteristics                                                                                       Main results
  --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Bronchiolitis                                                                                                                                 Kepreotes, \[[@b12-kjp-2019-00626]\] 2017                                  RCT, high flow (1 L/min/kg) vs. standard flow (2 L/min)                      N=202, \<24 months, moderate bronchiolitis                                                                     \- Lower rate of treatment failure in HFNC group
  \- No differences in duration of oxygen therapy and ICU transfer                                                                                                                                                                                                                                                                                                                                                     
  Franklin, \[[@b13-kjp-2019-00626]\] 2018                                                                                                      RCT, high flow (2 L/min/kg) vs. standard flow (2 L/min)                    N=1,472, \<12 months, mode- rate bronchiolitis                               \- Lower rate of treatment failure in HFNC group                                                               
  \- No differences in duration of oxygen therapy, hospital stay, and ICU transfer                                                                                                                                                                                                                                                                                                                                     
  Milesi, \[[@b14-kjp-2019-00626]\] 2018                                                                                                        RCT, high flow (2 L/min/kg) vs. high flow (3 L/min/kg)                     N=286, \<6 months, moderate to severe bronchiolitis                          \- No differences in the rate of treatment failure                                                             
  \- More discomfort in group with 3 L/kg/min                                                                                                                                                                                                                                                                                                                                                                          
  Lin, \[[@b19-kjp-2019-00626]\] 2019                                                                                                           Systematic review, 9 RCTs, HFNC vs. other oxy gen therapies (SOT, nCPAP)   N=2,121                                                                      vs. SOT and nCPAP                                                                                              
  \- No differences in length of stay, duration of oxygen therapy, ICU transfer, intubation rate, respiratory rate, SpO~2~ and adverse events                                                                                                                                                                                                                                                                          
  \- Significant reduction of the treatment failure (RR, 0.50; 95% CI, 0.40--0.62) compared with SOT group                                                                                                                                                                                                                                                                                                             
  \- Significant increase of the treatment failure (RR, 1.61; 95% CI, 1.06--2.42) compared with nCPAP group                                                                                                                                                                                                                                                                                                            
  \- Significant decreased of length of stay compared with SOT group in low-income and middle-income countries                                                                                                                                                                                                                                                                                                         
  Asthma                                                                                                                                        Baudin, \[[@b20-kjp-2019-00626]\] 2017                                     Retrospective observational study, HFNC vs. SOT                              N=73, 1--18 years, ICU patients with status asthmaticus                                                        \- Improvement in pH, pCO~2~, heart rate, respiration rate, and oxygenation in HFNC group compared to SOT group
  Ballestero, \[[@b21-kjp-2019-00626]\] 2018                                                                                                    Prospective randomized pilot trial, HFNC vs. SOT                           N=62, 1--14 years, ED patients with moderate-to-severe asthma exacerbation   \- At 2 hours after the start of therapy, improvement in pulmonary score in HFNC group compared to SOT group   
  Obstructive apnea/hypopnea                                                                                                                    Hawkins, \[[@b25-kjp-2019-00626]\] 2017                                    Observational study, HFNC 10--50 L/min                                       N=10, 1--18 years old, OSAS and CPAP intolerance                                                               \- Improvement in obstructive apnea-hypopnea index, SPO~2~, and heart rate in CPAP-intolerant children
  Joseph, \[[@b26-kjp-2019-00626]\] 2015                                                                                                        Retrospective review                                                       N=5, 2 months--15 years, OSAS and CPAP intolerance                           \- Improvement in apnea-hypopnea index and nadir oxygen saturation                                             
  Postextubation                                                                                                                                Shioji, \[[@b27-kjp-2019-00626]\] 2017                                     Retrospective observational study, pre-HFNC vs. post-HFNC                    N=20, \<48 months, postextubation respiratory failure after cardiac surgery                                    \- Improvement in respiration rate after HFNC apply
  Akyıldız, \[[@b28-kjp-2019-00626]\] 2018                                                                                                      RCT, HFNC vs. conventional oxygen therapy                                  N=100, 1 month--18 years, ICU patients after extubation                      \- Improvement in respiration rate, heart rate, end-tidal CO~2~, and atelectasis in HFNC group                 
  \- Lower failure rate of extubation in HFNC group                                                                                                                                                                                                                                                                                                                                                                    
  Pneumonia                                                                                                                                     Chisti, \[[@b29-kjp-2019-00626]\] 2015                                     Open RCT, HFNC vs. bubble CPAP vs. low-flow oxygen                           N=225, \<5 years old, severe pneumonia and hypoxemia                                                           \- No difference in the treatment failure after more than 1 hour of treatment between children with HFNC and bubble CPAP
  \- Study was early stopped because of higher mortality in the low-flow oxygen group                                                                                                                                                                                                                                                                                                                                  
  Respiratory distress                                                                                                                          Vitaliti, \[[@b30-kjp-2019-00626]\] 2017                                   Prospective observational study, HFNC vs. helmet CPAP                        N=60, 1--24 months, bronchiolitis (n=31), pneumoni a (n=7), asthma (n=2)                                       \- Improvement of respiratory distress both HFNC and helmet CPAP group, but helmet CPAP was more efficient and rapid compared with HFNC

RCT, randomized controlled trial; HFNC, high-flow nasal cannula; ICU, intensive care unit; SOT, standard oxygen therapy; nCPAP, nasal continuous positive airway pressure; CI, confidence interval; ED, Emergency Department; RR, risk ratio; OSAS, obstructive sleep apnea syndrome.
